News | November 30, 2025
MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Subscribe To Our Newsletter & Stay Updated
